Mitsubishi and Dewpoint partner in $480M ALS research collaboration

Dewpoint Therapeutics Inc. and Mitsubishi Tanabe Pharma Corp. (MTPC) have entered a research collaboration worth up to $480 million to develop Dewpoint’s novel TDP-43 small-molecule condensate modulator for the treatment of amyotrophic lateral sclerosis (ALS). Under the agreement, Dewpoint will receive an upfront payment and is eligible for milestone payments up to $480 million. If these milestones are reached, MTPC will have the option to license the program and take over global clinical development and commercialization. Dewpoint will also receive royalties on net sales. The collaboration aims to advance Dewpoint’s novel therapy for ALS, a debilitating neurological disease. The deal combines the expertise of both companies to accelerate the development of a potential new treatment for ALS patients.